Elacestrant
Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].
Product Specifications
CAS Number
722533-56-4
Product Name Alternative
RAD1901
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Elacestrant.html
Concentration
10mM
Purity
99.38
Solubility
DMSO : 160 mg/mL (ultrasonic)
Smiles
OC1=CC=C2C[C@H](C3=CC=C(OC)C=C3N(CC)CC4=CC=C(CCNCC)C=C4)CCC2=C1
Molecular Formula
C30H38N2O2
Molecular Weight
458.63
Precautions
H302, H312, H332
References & Citations
[1]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26 (9) :948-56.|[2]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23 (16) :4793-4804.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Biomed Pharmacother. 2024 Nov:180:117523.|bioRxiv. 2023 Nov 2.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|bioRxiv. 2025 Nov 21:2025.11.20.689560.|Genes Dev. 2025 Nov 5.|Harvard University. 2023 Mar. 30487357.|J Cell Mol Med. 2023 Sep;27 (17) :2467-2481.|NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2024 Nov 06.|Cancer Discov. 2024 Feb 8;14 (2) :274-289.|Cancer Res. 2024 Dec 16;84 (24) :4283-4297.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470393-500 1x 500 µL
Cytokeratin, multi (C11), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TRC-F700925-5G 5 g
4-Formylpiperidine-1-carboxylic Acid tert-Butyl Ester
Sign In for Pricing
View Details